Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026)

Caris Life Sciences' (CAI) quarterly Return on Capital Employed came in at 10.83% in Q1 2026, up 122.84% quarter-over-quarter from 4.86% in Q4 2025.

Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026) Analysis & Trends

Caris Life Sciences' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 10.83% for Q1 2026.

On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 10.83% in Q1 2026; TTM through Mar 2026 was 10.83%, a N/A change from a year earlier, with the FY2025 full-year figure at 7.43%, changed N/A from the prior year.
Return on Capital Employed rose to 10.83% in Q1 2026 per CAI's latest filing, from 4.86% in the prior quarter.
Across five years, Return on Capital Employed topped out at 10.83% in Q1 2026 and bottomed at 9.09% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-31.80%
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.46%
4	NuCana	279.75 Bn	279.75 Bn	-	-68.47%
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	21.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	10.19%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-68.84%
10	Caris Life Sciences	4.42 Bn	3.60 Bn	214.23 Mn	10.83%

Download Data